# A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

> **NCT03781219** · PHASE1 · UNKNOWN · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HL-085
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT03781219
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03781219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03781219, "A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03781219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*